Physician profile
Adam E Chornoby
NPI 1063790939
$6,499.23
in general payments reported to CMS, 2019-2025
33 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $359 · 2021: $262 · 2022: $769 · 2023: $1,591 · 2024: $1,656 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,437 · Travel and Lodging: $187 · Education: $31.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.51 |
| Travel and Lodging | $186.83 |
| Education | $31.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,094.19 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $647.64 | 2019-2024 | Xarelto |
| Medtronic, INC. | $507.14 | 2022-2025 | Micra, Venaseal, Turbohawk |
| Inari Medical, INC. | $499.71 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $471.93 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $353.31 | 2019-2025 | Farxiga, Andexxa |
| Novartis Pharmaceuticals Corporation | $323.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.20 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $226.80 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Abbott Laboratories | $222.48 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Amgen INC. | $204.42 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $202.35 | 2024-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $188.17 | 2022-2025 | Amvuttra |
| Scpharmaceuticals INC. | $172.83 | 2024-2025 | |
| Akcea Therapeutics, INC. | $120.76 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $104.57 | 2020-2025 | |
| Heartflow, INC. | $96.22 | 2024 | |
| Cordis US Corp. | $86.88 | 2024-2025 | Mynx Control |
| Lexicon Pharmaceuticals, INC. | $84.69 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $82.94 | 2020-2024 | Nexletol |
| Edwards Lifesciences Corporation | $74.87 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $74.07 | 2024-2025 | |
| Terumo Medical Corporation | $64.11 | 2021-2025 | Angio-Seal, Tr Band, Metacross Otw |
| Kestra Medical Technology Services, INC. | $53.59 | 2025 | Assure Wcd |
| Amarin Pharma, INC. | $49.51 | 2021-2022 | |
| Abiomed | $41.59 | 2023-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $36.86 | 2023-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $29.84 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $24.53 | 2019 | |
| Daiichi Sankyo INC. | $24.10 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $19.20 | 2022 | |
| Bardy Diagnostics, INC. | $18.55 | 2020 | |
| Vivaquant INC, Dba Rhythm Express | $14.06 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Chornoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.